Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug

Dow Jones

24 Mar

MW Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug

By Steve Goldstein

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player.

Novo Nordisk said it's paying $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the right to license a drug, outside of China that is in early-stage development to treat obesity, Type 2 diabetes and other diseases.

The candidate, currently called UBT251, is what's called a triple agonist of the receptors for GLP-1, GIP, and glucagon. In a Phase 1 trial, the highest dose group achieved an average weight loss of 15.1%, compared with 1.5% for the placebo.

Behind the Ozempic and Wegovy drugs to treat diabetes and weight loss, Novo Nordisk became Europe's top company by market cap, though it's now fallen from that perch.

Novo Nordisk shares (DK:NOVO.B) $(NVO)$ fell 3% on Monday and have dropped 18% this year, as the Danish drugmaker's trial of a key next-generation drug disappointed investors.

United Laboratories International shares (HK:3933) rallied 6% in Hong Kong trade, and have gained 35% this year.

-Steve Goldstein

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

March 24, 2025 06:55 ET (10:55 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2521538745"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521538745\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2521538745?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 18:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521538745","market":"hk","top_or_hot":-1,"title":"Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug\n</p>\n<p>\n  By Steve Goldstein \n</p>\n<p>\n     Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. \n</p>\n<p>\n     Novo Nordisk said it's paying $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the right to license a drug, outside of China that is in early-stage development to treat obesity, Type 2 diabetes and other diseases. \n</p>\n<p>\n     The candidate, currently called UBT251, is what's called a triple agonist of the receptors for GLP-1, GIP, and glucagon. In a Phase 1 trial, the highest dose group achieved an average weight loss of 15.1%, compared with 1.5% for the placebo. \n</p>\n<p>\n     Behind the Ozempic and Wegovy drugs to treat diabetes and weight loss, Novo Nordisk became Europe's top company by market cap, though it's now fallen from that perch. \n</p>\n<p>\n     Novo Nordisk shares (DK:NOVO.B) <a href=\"https://laohu8.com/S/NVO\">$(NVO)$</a> fell 3% on Monday and have dropped 18% this year, as the Danish drugmaker's trial of a key next-generation drug disappointed investors. \n</p>\n<p>\n     United Laboratories International shares (HK:3933) rallied 6% in Hong Kong trade, and have gained 35% this year. \n</p>\n<p>\n     -Steve Goldstein \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 06:55 ET (10:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-24 18:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug\n</p>\n<p>\n  By Steve Goldstein \n</p>\n<p>\n     Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. \n</p>\n<p>\n     Novo Nordisk said it's paying $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the right to license a drug, outside of China that is in early-stage development to treat obesity, Type 2 diabetes and other diseases. \n</p>\n<p>\n     The candidate, currently called UBT251, is what's called a triple agonist of the receptors for GLP-1, GIP, and glucagon. In a Phase 1 trial, the highest dose group achieved an average weight loss of 15.1%, compared with 1.5% for the placebo. \n</p>\n<p>\n     Behind the Ozempic and Wegovy drugs to treat diabetes and weight loss, Novo Nordisk became Europe's top company by market cap, though it's now fallen from that perch. \n</p>\n<p>\n     Novo Nordisk shares (DK:NOVO.B) <a href=\"https://laohu8.com/S/NVO\">$(NVO)$</a> fell 3% on Monday and have dropped 18% this year, as the Danish drugmaker's trial of a key next-generation drug disappointed investors. \n</p>\n<p>\n     United Laboratories International shares (HK:3933) rallied 6% in Hong Kong trade, and have gained 35% this year. \n</p>\n<p>\n     -Steve Goldstein \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 06:55 ET (10:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2521538745","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521538745","pubTimestamp":1742813700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player.Novo Nordisk said it's paying $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the right to license a drug, outside of China that is in early-stage development to treat obesity, Type 2 diabetes and other diseases.The candidate, currently called UBT251, is what's called a triple agonist of the receptors for GLP-1, GIP, and glucagon. In a Phase 1 trial, the highest dose group achieved an average weight loss of 15.1%, compared with 1.5% for the placebo.Behind the Ozempic and Wegovy drugs to treat diabetes and weight loss, Novo Nordisk became Europe's top company by market cap, though it's now fallen from that perch.Novo Nordisk shares   fell 3% on Monday and have dropped 18% this year, as the Danish drugmaker's trial of a key next-generation drug disappointed investors","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德","BK4007":"制药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","03933":"联邦制药","BK4599":"减肥药","BK4532":"文艺复兴科技持仓","BK4144":"石油与天然气的储存和运输","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4590":"PTP","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK1191":"制药","ULIHF":"United Laboratories International Holdings Ltd.","GLP":"全球合伙","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"诺和诺德与一家生产GLP-1药物的中国公司达成20亿美元协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":0.9,"GLP":1,"NVO":1,"ULIHF":0.9},"content_text":"MW Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug\n\n\n  By Steve Goldstein \n\n\n     Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. \n\n\n     Novo Nordisk said it's paying $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the right to license a drug, outside of China that is in early-stage development to treat obesity, Type 2 diabetes and other diseases. \n\n\n     The candidate, currently called UBT251, is what's called a triple agonist of the receptors for GLP-1, GIP, and glucagon. In a Phase 1 trial, the highest dose group achieved an average weight loss of 15.1%, compared with 1.5% for the placebo. \n\n\n     Behind the Ozempic and Wegovy drugs to treat diabetes and weight loss, Novo Nordisk became Europe's top company by market cap, though it's now fallen from that perch. \n\n\n     Novo Nordisk shares (DK:NOVO.B) $(NVO)$ fell 3% on Monday and have dropped 18% this year, as the Danish drugmaker's trial of a key next-generation drug disappointed investors. \n\n\n     United Laboratories International shares (HK:3933) rallied 6% in Hong Kong trade, and have gained 35% this year. \n\n\n     -Steve Goldstein \n\n\n     This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 06:55 ET (10:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}